| Cat.No. | Name | Information |
|---|---|---|
| M13754 | OSU-T315 | OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
| M13752 | BIO-1211 | BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively. |
| M9173 | Cilengitide TFA | Cilengitide TFA is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M59039 | αvβ1 integrin-IN-1 | αvβ1 integrin-IN-1 is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. αvβ1 integrin-IN-1 has antifibrotic effects. |
| M58555 | Volociximab | Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| M54396 | LDV | LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
| M54150 | Cyclo(RADfK) | Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
| M54037 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. |
| M53341 | α2β1 Integrin Ligand Peptide | α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. |
| M45157 | OS2966 | OS2966 is a first-in-class (first-in-class) neutralizing anti-CD29 monoclonal antibody that selectively modulates CD29 (integrin b1 subunit) and can be used in glioblastoma-related studies. |
| M45151 | Lifitegrast sodium | Lifitegrast sodium is a potent integrin antagonist that blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen (LFA-1) and interrupts the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits the attachment of Jurkat T cells to ICAM-1 with an IC50 of 2.98 nM.May be useful in studies related to dry eye. |
| M45137 | Fuzapladib | Fuzapladib is a leukocyte adhesion molecule and an orally active inhibitor of leukocyte function-associated antigen type 1 (LFA-1) activation.Fuzapladib is also a phospholipase A2 (PLA2) inhibitor, which exerts anti-inflammatory activity by inhibiting the migration of leukocytes to sites of inflammation. |
| M40619 | Dentonin acetate | Dentonin acetate is an amino acid peptide derived from matrix extracellular phosphoglycoprotein (MEPE) and has the ability to promote the proliferation of dental pulp stem cells (DPSCs), which can be used in studies related to endodontic restoration and osteoarthritis (OA). |
| M30828 | BMS-688521 | BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model. |
| M29738 | ATN-161 | ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
| M29565 | Bexotegrast | Bexotegrast is a potent inhibitor of ανβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). |
| M25268 | Etaracizumab | Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer. |
| M24843 | Natalizumab | Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
